^
Association details:
| Biomarker: | ERCC1 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Predictive value of KRAS mutation & excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen
Published date:
01/16/2021
Excerpt:
There were no significant differences in disease-free survival or overall survival in groups separated by KRAS mutation and ERCC1 expression status. Subgroup analysis of patients with wild-type KRAS showed that overall survival in the ERCC1 overexpression group was lower than that of patients in the ERCC1 underexpression group (p = 0.029); however, no significant difference was found in the mutant KRAS patient group (p = 0.671).
DOI:
10.1016/j.asjsur.2020.12.028
